A Phase 3 interventional study of Adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 92 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-31.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 846 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 5th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2000, is one of 14 in phase 3, and was the 2nd registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
Study DE020 was a multicenter, open-label continuation study for patients with rheumatoid arthritis who had participated in a prior Phase 1, 2, or 3 adalimumab study in the United States or Canada, had a favorable safety and efficacy profile when treated with adalimumab, and met the eligibility criteria for the continuation study. Participants received subcutaneous injections of adalimumab every other week (eow) or monthly based on the adalimumab regimen received in the prior study (i.e., participants who received monthly dosing in the prior study began the continuation study on monthly dosing; all other participants began adalimumab dosing at eow intervals). Participants who maintained an American College of Rheumatology 50% (ACR50) response for 2 consecutive visits could have their dosing interval lengthened to a monthly dosing schedule. Safety and efficacy data were collected over 520 weeks (10 years). Both safety and efficacy data were analyzed using all participants who received at least 1 dose of open-label adalimumab in the 10-year continuation study DE020 (the Full Analysis Set, n=846). Three patients who entered the continuation study but were never dosed were excluded from all analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Open-label adalimumab 40 mg
Biological: Adalimumab
Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
Also known as: Humira, ABT-D2E7
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520
ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 520
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260
ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 260
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520
ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 520
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260
ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 260
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520
ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 520
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260
ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
Time frame: Week 260
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520
Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).
Time frame: Week 520
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260
Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).
Time frame: Week 260
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520
The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.
Time frame: Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 520
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260
The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.
Time frame: Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 260
Reported Adverse Events
Adverse events were collected during the course of the study (after the first adalimumab injection in this continuation study DE020 through 70 days after the last adalimumab injection) for all participants who received at least 1 dose of open-label adalimumab in the continuation study (Full Analysis Set). The number of participants experiencing any adverse event (serious and non-serious) are summarized. See the Reported Adverse Events section for details.
Time frame: Duration of study (up to 520 weeks [10 years])
| Milestone | Adalimumab |
|---|---|
| Started | 846 |
| Completed | 321 |
| Not completed | 525 |
| Withdrew: Adverse event | 194 |
| Withdrew: Lack of efficacy | 99 |
| Withdrew: Withdrawal by subject | 67 |
| Withdrew: Lost to follow-up | 44 |
| Withdrew: Death | 23 |
| Withdrew: Protocol violation | 15 |
| Withdrew: Administrative reasons | 83 |
ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520 | 187 |
ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260 | 402 |
ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520 | 132 |
Adverse events were collected during the course of the study (after the first adalimumab injection in this continuation study DE020 through 70 days after the last adalimumab injection) for all participants who received at least 1 dose of open-label adalimumab in the continuation study (Full Analysis Set). The number of participants experiencing any adverse event (serious and non-serious) are summarized. See the Reported Adverse Events section for details.
| participants | Adalimumab |
|---|---|
| Reported Adverse Events | 808 |
ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260 | 279 |
ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520 | 78 |
ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.
| participants | Adalimumab |
|---|---|
| Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260 | 179 |
Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).
| participants | Adalimumab |
|---|---|
| Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520 | 135 |
Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).
| participants | Adalimumab |
|---|---|
| Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260 | 243 |
The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.
| units on a scale | Adalimumab |
|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520 | -0.52 ± 0.662 |
The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.
| units on a scale | Adalimumab |
|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260 | -0.59 ± 0.628 |
Collected over After the first adalimumab injection in this continuation study DE020 to 70 days after the last adalimumab injection.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 432/846 (51.1%) | 768/846 (90.8%) |
| Event | Adalimumab |
|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 73/846 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 44/846 |
| PneumoniaInfections and infestations | 36/846 |
| CellulitisInfections and infestations | 20/846 |
| Angina pectorisCardiac disorders | 14/846 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/846 |
| Coronary artery diseaseCardiac disorders | 10/846 |
| Myocardial infarctionCardiac disorders | 10/846 |
| Atrial fibrillationCardiac disorders | 9/846 |
| Cerebrovascular accidentNervous system disorders | 9/846 |
| Event | Adalimumab |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 392/846 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 215/846 |
| SinusitisInfections and infestations | 211/846 |
| NasopharyngitisInfections and infestations | 193/846 |
| BronchitisInfections and infestations | 179/846 |
| HypertensionVascular disorders | 176/846 |
| Urinary tract infectionInfections and infestations | 170/846 |
| Back painMusculoskeletal and connective tissue disorders | 147/846 |
| DiarrhoeaGastrointestinal disorders | 134/846 |
| RashSkin and subcutaneous tissue disorders | 131/846 |
| Age Continuous(years) | Adalimumab |
|---|---|
| Mean | 55.6 ± 12.19 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 661 |
| Male | 185 |
The record gives a start of Jul 2000, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab